1. Chemoembolization versus radioembolization for the treatment of unresectable intrahepatic cholangiocarcinoma in a single institution image-based efficacy and comparative toxicity
- Author
-
Veer Shah, Christopher Noda, Eric J Weiner, Gretchen Foltz, Olaguoke Akinwande, Nael Saad, and Abigail Mills
- Subjects
medicine.medical_specialty ,Chemotherapy ,Prior Surgery ,Hepatology ,business.industry ,medicine.medical_treatment ,Tumor burden ,Gastroenterology ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,Oncology ,030220 oncology & carcinogenesis ,Internal medicine ,Toxicity ,medicine ,Single institution ,business ,Adverse effect ,Image based ,Intrahepatic Cholangiocarcinoma ,Research Article - Abstract
Aim: Compare radioembolization (Y90) and chemoembolization (CE) for the treatment of unresectable intrahepatic cholangiocarcinoma (UICC). Materials & methods: Institutional Review Board-approved, retrospective search was performed. Forty patients with UICC were treated with either Y90 (n = 25, 39 treatments) or CE (n = 15, 35 treatments). Comparative analysis was performed using Student's t and fisher-exact tests. Multivariable-logistic regression was also performed. Results: Median ages were 60 and 64 years for CE and Y90 groups, respectively (p = 0.798). Patient variables including age, Eastern Cooperative Oncology Group score, tumor burden, extra-hepatic disease, prior chemotherapy and prior surgery were similar between groups. Adverse events were similar in both groups (CE 20%, Y90 26%; p > 0.9). Overall response rate (CE 6%, Y90 4%; p > 0.9) and disease control rate (CE 46%, Y90 48%; p > 0.9) were statistically similar. Multilogistic regression did not identify any variables that correlated with disease control rate, including Eastern Cooperative Oncology Group score and tumor burden. Conclusion: Our observation shows that CE and Y90 display similar toxicity and disease control in the treatment of UICC.
- Published
- 2017